Overview

Donafenib Monotherapy for Previously Treated Metastatic Gastric Cancer

Status:
Suspended
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
This open-label, one-center, noncomparative, two-stage phase 1B trial assessed the donafenib in advanced gastric cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Suzhou Zelgen Biopharmaceuticals Co.,Ltd